Dose-Response: Potency vs. Efficacy — Dose–response curves: potency vs efficacy - Pharmacology

SECTION 1

Historical Context & Motivation

The relationship between the dose of a substance and the magnitude of its biological effect has fascinated scientists for centuries. Even Paracelsus, writing in the sixteenth century, recognized that "the dose makes the poison," articulating the foundational insight that no substance is inherently toxic or benign—only the quantity determines the outcome. However, it was not until the twentieth century that pharmacologists developed the rigorous, quantitative frameworks needed to characterize dose–response relationships with mathematical precision. The emergence of these frameworks transformed drug development and clinical therapeutics, enabling physicians to compare drugs rationally and select agents based on quantitative parameters rather than empirical trial alone.

1854 • Claude Bernard and Receptor Specificity

Claude Bernard demonstrated that curare acts at the neuromuscular junction rather than on the nerve or muscle directly, establishing the concept of site-specific drug action and laying groundwork for quantitative pharmacology.

1905 • Langley's Receptive Substance

John Newport Langley proposed the existence of a "receptive substance" on cells to which drugs and toxins bind, forming the basis of modern receptor theory and enabling formal dose–response analysis.

1937 • Clark's Occupation Theory

A. J. Clark published quantitative data showing that drug effects are proportional to the fraction of receptors occupied, introducing the mathematical dose–response curve and the concept of maximal response.

1954 • Ariens and Intrinsic Activity

E. J. Ariëns introduced the concept of intrinsic activity (α), formally distinguishing between a drug's ability to bind a receptor (affinity) and its capacity to activate that receptor—separating potency from efficacy conceptually.

1956 • Stephenson's Efficacy Concept

R. P. Stephenson refined Ariëns' work by defining efficacy (e) as an independent parameter, demonstrating that drugs with identical receptor affinity could produce vastly different maximal effects, completing the modern distinction between potency and efficacy.

These historical advances converge on a central clinical question: when two drugs treat the same condition, how do we decide which is superior? The dose–response curve provides the answer by quantifying two independent parameters—potency (how much drug is needed) and efficacy (how large a response can be achieved)—that together determine a drug's therapeutic utility.

SECTION 2

Core Principles & Definitions

Understanding dose–response curves requires familiarity with several interrelated pharmacological concepts. A graded dose–response curve plots the magnitude of a biological response (y-axis) against the log of drug concentration or dose (x-axis), yielding a characteristic sigmoidal (S-shaped) curve. This curve encodes two critical pieces of information: the position of the curve along the x-axis reflects potency, while the plateau height on the y-axis reflects efficacy. These are independent properties; a drug can be highly potent yet have low efficacy, or it can be less potent but achieve a greater maximal effect.

Potency (EC₅₀ / ED₅₀)

Potency refers to the amount of drug required to produce a given effect. It is quantified by the EC₅₀ (concentration producing 50% of maximal effect) or ED₅₀ (dose producing 50% of maximal effect). A lower EC₅₀ means higher potency.

Efficacy (E_max)

Efficacy is the maximal response (E_max) a drug can produce regardless of dose. It reflects intrinsic activity at the receptor level and is the clinical ceiling of the drug's therapeutic effect.

Affinity ( $K_d$ )

Affinity describes how tightly a drug binds to its receptor, quantified by the dissociation constant (K_d). A lower K_d indicates higher affinity. Affinity contributes to potency but does not determine efficacy.

Intrinsic Activity (α)

Intrinsic activity ranges from 0 to 1 and reflects the ability of a drug–receptor complex to initiate a signal. A full agonist has α = 1, a partial agonist has 0 < α < 1, and an antagonist has α = 0.

Log-Dose Axis

Dose–response data are plotted on a logarithmic x-axis because drug concentrations span several orders of magnitude. This transformation converts the hyperbolic binding curve into a sigmoidal curve with a near-linear central portion, facilitating visual comparison of EC₅₀ values.

✦

KEY TAKEAWAY

Think of potency and efficacy like a car's gas pedal. Potency is how far you need to press the pedal to reach cruising speed—a sensitive pedal requires less pressure (lower dose). Efficacy is the car's top speed—no matter how hard you press, the engine has a maximum output. A sports car (high efficacy) may need the same pedal pressure as a compact (same potency) but reaches a much higher top speed.

SECTION 3

Visual Explanation — The Graded Dose–Response Curve

This diagram shows three dose–response curves plotted on a log-concentration axis. Drug A (cyan) is the most potent (lowest EC₅₀) and has the highest efficacy (E_max). Drug B (violet) is a full agonist with less potency but still substantial efficacy. Drug C (pink, dashed) is a partial agonist—regardless of dose, it cannot achieve the same E_max as the full agonists.

Several features of this diagram deserve careful attention. First, notice that potency is a horizontal comparison: Drug A's curve lies to the left of Drug B's, meaning Drug A achieves 50% of its maximal effect at a lower concentration—its EC₅₀ is smaller, making it more potent. Second, efficacy is a vertical comparison: both Drug A and Drug B reach similar ceiling responses (they are full agonists), whereas Drug C plateaus at a lower maximum (it is a partial agonist). The clinical implication is crucial: potency determines the dose written on the prescription, but efficacy determines whether the drug can achieve the therapeutic goal at all.

💡

Clinical Pearl

A common exam pitfall: students often assume a more potent drug is a "better" drug. In clinical practice, efficacy is typically more clinically important than potency. Potency mainly affects the dose size. For example, hydrochlorothiazide at 25 mg and chlorthalidone at 12.5 mg may achieve similar effects—chlorthalidone is more potent (lower dose needed), but both are equally efficacious if they lower blood pressure to the same degree.

SECTION 4

Mathematical Framework

The mathematical description of dose–response relationships derives from the law of mass action applied to drug–receptor binding. The simplest model assumes that a drug (D) reversibly binds to a receptor (R) to form a drug–receptor complex (DR), and that the biological effect is proportional to the fraction of receptors occupied. This framework, originally formalized by A. J. Clark, provides the foundation for quantitative pharmacology.

RECEPTOR OCCUPANCY

Fractional Occupancy = [D] / ([D] + K_d)

Where [D] = concentration of free drug, and K_d = dissociation constant (the concentration at which 50% of receptors are occupied). A smaller K_d indicates higher affinity.

GRADED DOSE–RESPONSE (HILL EQUATION)

E = E_max × [D]ⁿ / ([D]ⁿ + EC₅₀ⁿ)

Where E = observed effect, E_max = maximal possible effect (efficacy), EC₅₀ = concentration producing 50% of E_max (reflects potency), and n = Hill coefficient (describes the steepness of the curve; n = 1 for simple receptor binding, n > 1 for cooperative binding).

The Hill equation is the single most important equation in quantitative pharmacology for this topic. When graphed on a log-[D] axis, it produces the characteristic sigmoid curve. At low concentrations (where [D] ≪ EC₅₀), the effect increases nearly linearly with concentration. At high concentrations (where [D] ≫ EC₅₀), the effect asymptotically approaches E_max. The inflection point of the sigmoid occurs precisely at EC₅₀, which is the pharmacological measure of potency.

RELATIONSHIP BETWEEN $K_d$ AND EC₅₀

EC₅₀ = K_d / (e × R_T)

In the simplified Clark model (no spare receptors, full agonist), EC₅₀ ≈ K_d. However, in the presence of receptor reserve (spare receptors), EC₅₀ < K_d because maximal response can be achieved without full receptor occupancy. Here, e = Stephenson's efficacy and R_T = total receptor number.

⚠

When EC₅₀ ≠ $K_d$

Students frequently confuse EC₅₀ with K_d. They are equal only when there is a 1:1 linear relationship between receptor occupancy and response. In tissues with spare receptors (receptor reserve), the maximal effect occurs before all receptors are occupied, so EC₅₀ is lower than K_d. This concept is especially relevant for understanding why partial agonists are less affected by receptor reserve.

SECTION 5

Drug Classification by Potency and Efficacy

Drugs can be systematically classified by their intrinsic activity (α) and their position on the dose–response curve. This classification has direct therapeutic implications: the choice between a full agonist, partial agonist, or antagonist depends on the clinical scenario, the disease pathophysiology, and the desired degree of receptor activation.

Left panel: dose–response curves for four drug classes. The full agonist (green) reaches 100% E_max; the partial agonist (amber) plateaus below the system maximum; the inverse agonist (pink, dashed) would push response below baseline (not fully shown); and the antagonist (red, dashed) produces no response alone. Right panel: classification summary with clinical examples.

Parameter	Potency	Efficacy
Definition	Amount of drug needed to produce a given effect	Maximum effect a drug can produce
Measured by	EC₅₀ or ED₅₀ (lower = more potent)	E_max (higher = more efficacious)
Read on curve	Horizontal position (left = more potent)	Vertical height of plateau
Determined by	Affinity (K_d) + intrinsic activity + receptor reserve	Intrinsic activity (α) of the drug
Clinical relevance	Determines dose size; rarely determines drug choice	Determines whether therapeutic goal can be achieved
Example	Hydromorphone is more potent than morphine (needs ~1.5 mg vs 10 mg IV for same effect)	Morphine (full agonist) has greater efficacy than buprenorphine (partial agonist) for pain relief ceiling

Comparison of Potency and Efficacy

SECTION 6

Worked Example — Comparing Two Analgesics

Consider the following clinical scenario: a pharmacology researcher measures the dose–response data for two opioid analgesics in an in vitro assay. Drug X achieves an E_max of 95% of the system maximum with an EC₅₀ of 10 nM. Drug Y achieves an E_max of 60% with an EC₅₀ of 2 nM. The Hill coefficient (n) is 1 for both drugs. Determine which drug is more potent, which is more efficacious, and calculate the expected response of each drug at a concentration of 5 nM.

Comparing Drug X and Drug Y

1
Step 1 — Identify Potency

Potency is inversely related to EC₅₀. Drug X has EC₅₀ = 10 nM, while Drug Y has EC₅₀ = 2 nM. Since Drug Y requires a lower concentration to achieve 50% of its maximum effect, Drug Y is more potent.

Drug Y is 5× more potent than Drug X (EC₅₀ ratio: 10 nM / 2 nM = 5).
2
Step 2 — Identify Efficacy

Efficacy corresponds to E_max. Drug X achieves 95% of the system maximum, while Drug Y achieves only 60%. Therefore, Drug X is more efficacious.

Drug X E_max = 95%; Drug Y E_max = 60%.
3
Step 3 — Apply Hill Equation for Drug X at [D] = 5 nM

Using E = E_max × [D]ⁿ / ([D]ⁿ + EC₅₀ⁿ) with n = 1: E = 95% × 5 / (5 + 10) = 95% × 5/15 = 95% × 0.333 = 31.7% of the system maximum.

Drug X at 5 nM → E = 31.7% of system maximum.
4
Step 4 — Apply Hill Equation for Drug Y at [D] = 5 nM

E = 60% × 5 / (5 + 2) = 60% × 5/7 = 60% × 0.714 = 42.9% of the system maximum.

Drug Y at 5 nM → E = 42.9% of system maximum.
5
Step 5 — Clinical Interpretation

At 5 nM, Drug Y produces a greater effect (42.9%) than Drug X (31.7%) because Drug Y is more potent—its EC₅₀ is lower, so at any submaximal concentration, a higher fraction of its maximal response is achieved. However, Drug X can ultimately produce a larger maximal response (95% vs. 60%). In clinical practice, if the therapeutic goal requires a response greater than 60% of the system maximum, only Drug X can achieve that goal, demonstrating why efficacy often trumps potency in drug selection.

Drug Y is more potent; Drug X is more efficacious. Drug selection depends on the therapeutic target.

SECTION 7

Clinical Significance — When Potency and Efficacy Matter

In clinical pharmacology, the distinction between potency and efficacy directly influences prescribing decisions, drug formulation, and patient safety. The following table illustrates real-world therapeutic scenarios where one parameter may take precedence over the other, helping clinicians make rational drug choices.

Clinical Scenario	Key Parameter	Rationale
Choosing between two equally efficacious diuretics	Potency	If both drugs produce the same maximal diuresis, the more potent one allows a smaller pill size and possibly fewer side effects from inactive ingredients.
Treating severe cancer pain	Efficacy	A full agonist opioid (e.g., morphine) is needed over a partial agonist (e.g., buprenorphine) because the therapeutic goal requires high E_max.
Maintenance therapy for opioid use disorder	Efficacy (ceiling effect)	Buprenorphine's partial agonism provides analgesia while limiting respiratory depression—its ceiling effect (lower E_max) is the safety advantage.
Topical vs. systemic corticosteroids	Potency	Highly potent topical steroids (clobetasol) achieve effective local concentrations at low doses, minimizing systemic absorption and adverse effects.
Antihypertensive therapy selection	Efficacy + Safety profile	The therapeutic ceiling determines the maximal blood pressure reduction achievable; the therapeutic index (related to ED₅₀ and TD₅₀) determines the safety margin.

Clinical Scenarios Highlighting Potency vs. Efficacy

✦

KEY TAKEAWAY

Imagine hiring a weightlifter versus a marathon runner for different tasks. A potent drug is like a weightlifter who can do the job with minimal effort—you don't need much of it. An efficacious drug is like hiring someone with the highest maximum lift capacity—they can handle the heaviest load. In clinical medicine, you want to match the drug's ceiling (efficacy) to the disease's demands and use potency to optimize dosing convenience.

SECTION 8

Connection to Advanced Pharmacological Concepts

The potency–efficacy framework extends into several advanced topics in pharmacology and therapeutics. Understanding how these basic parameters connect to more complex concepts prepares you for clinical reasoning about drug interactions, therapeutic indices, and receptor dynamics in disease states.

Basic Concept	Advanced Extension	Clinical Relevance
EC₅₀ (potency)	Therapeutic Index (TI = TD₅₀/ED₅₀)	The ratio of toxic dose to effective dose; a narrow TI (e.g., warfarin, lithium) demands precise dosing and therapeutic drug monitoring.
E_max (efficacy)	Receptor Reserve (Spare Receptors)	Tissues with spare receptors can achieve E_max without full receptor occupancy, making EC₅₀ appear lower than K_d. Loss of receptors (e.g., receptor downregulation) reduces this reserve.
Partial agonist efficacy	Functional Antagonism	A partial agonist in the presence of a full agonist can act as a functional antagonist by occupying receptors and reducing the overall response—the basis for buprenorphine's use in opioid dependence.
Log dose–response curve	Quantal Dose–Response	While graded curves measure effect magnitude in one system, quantal curves plot the cumulative percentage of a population responding vs. dose—used to derive ED₅₀, TD₅₀, and LD₅₀ in populations.
Intrinsic activity (α)	Two-State Receptor Model	Modern receptor theory postulates that receptors exist in active (R) and inactive (R) conformations at equilibrium. Agonists stabilize R, inverse agonists stabilize R, and neutral antagonists do not shift the equilibrium.

From Dose–Response Basics to Advanced Pharmacology

The graded dose–response curve is the starting point, but clinical pharmacology demands that you also understand quantal dose–response relationships, which shift the question from "how much effect?" to "what fraction of patients respond?" In subsequent coursework, you will encounter Schild plots for characterizing competitive antagonism, concentration–effect relationships for multiple drug combinations (isobolograms), and pharmacokinetic–pharmacodynamic (PK/PD) modeling that integrates dose–response data with drug absorption, distribution, metabolism, and excretion.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Drug A has an EC₅₀ of 5 nM and an E_max of 100%. Drug B has an EC₅₀ of 500 nM and an E_max of 100%. Which drug is more potent? Which is more efficacious? Could a physician substitute one for the other? Explain your reasoning.

Show answer

Drug A is more potent because its EC₅₀ (5 nM) is 100-fold lower than Drug B's (500 nM), meaning Drug A achieves 50% of its maximal effect at a much lower concentration. Both drugs are equally efficacious, as they share the same E_max of 100%. Since efficacy is identical, a physician could theoretically substitute one for the other by adjusting the dose accordingly—Drug B would simply require a higher dose (roughly 100-fold) to produce the same magnitude of effect. In practice, the substitution would depend on additional factors such as side-effect profiles, drug formulation, and cost.

Question 2: BASIC CALCULATION

A drug has an E_max of 80% and an EC₅₀ of 20 nM (Hill coefficient n = 1). Using the Hill equation, calculate the expected response at a concentration of 60 nM.

Show answer

Applying the Hill equation: E = E_max × [D] / ([D] + EC₅₀) = 80% × 60 / (60 + 20) = 80% × 60/80 = 80% × 0.75 = 60%. At a concentration of 60 nM, the drug produces a response equal to 60% of the system maximum. Note that at three times the EC₅₀, the drug has reached 75% of its own E_max (60/80 = 0.75), illustrating the hyperbolic approach toward the ceiling.

Question 3: INTERMEDIATE

Two full agonists (Drug P and Drug Q) act on the same receptor. Drug P has EC₅₀ = 1 µM and Drug Q has EC₅₀ = 10 µM. In a tissue known to have a large receptor reserve, an irreversible antagonist is administered that eliminates 90% of receptors. Predict the qualitative effect on the dose–response curves of both drugs.

Show answer

With a large receptor reserve, both drugs initially achieve E_max without occupying all receptors. After irreversible antagonist eliminates 90% of receptors, the spare receptor buffer is largely consumed. For Drug P (higher potency), the remaining 10% of receptors may still be sufficient to achieve near-maximal response if the original reserve was very large, but its EC₅₀ will shift rightward (apparent decrease in potency). For Drug Q (lower potency), the loss of 90% of receptors will likely reduce both potency (rightward shift of EC₅₀) and efficacy (decreased E_max), because there are now insufficient receptors for the less potent drug to generate a full response. This differential effect is a classic demonstration of how receptor reserve protects potent drugs but cannot fully compensate for less potent agents.

Question 4: APPLIED

A patient with chronic pain is currently receiving morphine (a full µ-opioid agonist) for analgesia. The physician considers switching to buprenorphine (a partial µ-opioid agonist) for its improved safety profile. Buprenorphine is more potent than morphine (lower EC₅₀) but has lower efficacy (E_max ≈ 50–60% of full agonist). Under what clinical circumstances might this switch be problematic, and when might it be beneficial?

Show answer

The switch would be problematic for patients requiring high levels of analgesia (e.g., severe cancer pain) because buprenorphine's ceiling effect limits the maximal pain relief achievable—no matter how much buprenorphine is administered, it cannot match morphine's full E_max. Additionally, in a patient physically dependent on morphine, adding buprenorphine could precipitate withdrawal because the partial agonist displaces the full agonist from receptors while providing less receptor activation. Conversely, buprenorphine's ceiling effect is beneficial in opioid use disorder maintenance therapy because it limits respiratory depression (a dose-dependent full agonist effect), reducing overdose risk. The lower efficacy at the µ-receptor provides sufficient effect to prevent withdrawal symptoms and cravings while maintaining a safety margin—a prime example of deliberately choosing lower efficacy for therapeutic benefit.

Question 5: CRITICAL THINKING

Consider a hypothetical receptor system where two drugs (M and N) have identical affinity (K_d = 50 nM) and identical intrinsic activity (α = 1). However, Drug M has EC₅₀ = 5 nM and Drug N has EC₅₀ = 50 nM when measured in the same tissue. How can two drugs with identical K_d and identical α values have different EC₅₀ values? What does this tell you about the limitation of Clark's occupation theory?

Show answer

This apparent paradox arises because EC₅₀ and K_d are equal only when there is a strict linear relationship between receptor occupancy and response (Clark's original assumption). In reality, drugs differ in their ability to trigger downstream signal transduction per occupied receptor—what Stephenson termed 'efficacy' (e). Drug M, despite having the same binding affinity as Drug N, may be more efficient at coupling receptor occupation to G-protein activation, second messenger production, or other intracellular cascades. This higher coupling efficiency means Drug M can achieve 50% of E_max while occupying fewer receptors—hence EC₅₀ < K_d. Drug N, with lower coupling efficiency, requires near-full receptor occupancy to reach 50% response, so EC₅₀ ≈ K_d. This demonstrates a key limitation of Clark's model: it equates receptor occupancy with response. Modern receptor theory (Stephenson, Furchgott) separates binding from activation, acknowledging that efficacy is a drug-specific property independent of affinity—and that spare receptors amplify the difference between EC₅₀ and K_d for drugs with high coupling efficiency.

SUMMARY

Summary — Dose–Response: Potency vs. Efficacy

Summary

The graded dose–response curve is the foundational tool for comparing drugs quantitatively. Two independent parameters extracted from this curve— potency (EC₅₀) and efficacy (E_max)—capture different aspects of drug action. Potency, read as the horizontal position of the curve, reflects the dose required to produce a given effect and is determined by receptor affinity ( $K_d$ ), intrinsic activity, and receptor reserve. Efficacy, read as the plateau height, reflects the maximum achievable response and is determined by intrinsic activity (α). The Hill equation provides the mathematical framework linking these parameters: E = E_max × [D]ⁿ / ([D]ⁿ + EC₅₀ⁿ).

Clinically, efficacy is generally more important than potency because it determines whether a drug can achieve the desired therapeutic effect at any dose. Potency primarily influences dosing convenience and formulation. Full agonists (α = 1) achieve maximal system response; partial agonists (0 < α < 1) have an intrinsic ceiling and can act as functional antagonists in the presence of full agonists. Understanding these principles is essential for rational drug selection, predicting drug interactions, and interpreting clinical pharmacology literature.